William Blair analyst Matt Larew has maintained their bullish stance on OPCH stock, giving a Buy rating on April 22.
Matt Larew has given his Buy rating due to a combination of factors that highlight Option Care Health’s strong financial performance and promising outlook. The company reported first-quarter results that exceeded both the firm’s and consensus estimates, showcasing robust growth in net revenue, adjusted EBITDA, and adjusted EPS. This consistent outperformance, marked by a 21st consecutive quarter of results surpassing expectations, underscores the company’s resilient growth strategy.
Moreover, Option Care Health has raised its full-year guidance, projecting increased revenue and profitability despite facing some pricing headwinds. The updated guidance reflects confidence in the company’s ability to manage challenges and sustain its growth trajectory, with expectations for adjusted EBITDA and EPS to grow even in a year of slower top-line growth. These factors collectively support Matt Larew’s positive outlook and Buy rating for the stock.
According to TipRanks, Larew is an analyst with an average return of -8.0% and a 38.46% success rate. Larew covers the Healthcare sector, focusing on stocks such as 908 Devices, Option Care Health, and Repligen.
In another report released on April 22, JMP Securities also reiterated a Buy rating on the stock with a $36.00 price target.